Development of a Manufacturing and Cell Processing Center for Investigational Drugs
First written in FY2016. 12 of 18 entries say "Advanced", first in FY2019. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「In the production business, contract manufacturing of vaccine drug substance in 2021 led us to identify potential in a contract manufacturing business that uses our production technologies and expertise. In July 2025, we were selected to receive a subsidy under the Ministry of Economy, Trade and Industry's Subsidy Program for Manufacturing Equipment for Regenerative Medicine, Cell Therapy and Gene Therapy. The new formulation plant, for which construction began in February 2025, is progressing smoothly toward completion during fiscal 2026.」
The new formulation plant now has total planned investment of ¥25 billion, ¥14.9 billion already paid, and completion scheduled for September 2026. Capital expenditures are ¥10,740 million, and the expansion of manufacturing capacity is under way. In addition, the Advanced Biopharmaceutical Research Institute commenced operations on 1 April 2026. - FY2025AdvancedAnnual report
「Kobe Science Park Formulation Plant (provisional name); ¥25,000 million; ¥7,100 million; subsidies and internal funds; February 2025; September 2026; expansion of pharmaceutical manufacturing capacity.」
The Kobe Science Park Formulation Plant (provisional name) proceeded as planned, with construction beginning in February 2025, total planned investment of ¥25 billion, ¥7.1 billion already paid, and completion scheduled for September 2026. - FY2025-H1Exclusion from the Equity-Method ScopeAnnual report
「During the interim consolidated accounting period, Mycenax Biotech Inc. was excluded from the scope of equity-method accounting following the sale of part of its shares.」
Mycenax Biotech Inc., with which the Company had been strengthening its relationship to increase production capacity flexibility, was excluded from the scope of equity-method accounting following the sale of part of its shares. The Company has not explained the reason for the sale or its impact on production capacity in the main text. - FY2024AdvancedAnnual report
「Kobe Science Park Formulation Plant (provisional name); ¥25,000 million; 27; subsidies and internal funds; December 2024; January 2027; expansion of pharmaceutical manufacturing capacity.」
The total planned investment in the new formulation plant is ¥25 billion, with construction scheduled to begin in December 2024 and completion scheduled for January 2027. The plan is to expand pharmaceutical manufacturing capacity using subsidies and internal funds. - FY2024-Q2AchievedAnnual report
「The Kobe Science Park Center was completed in November 2022 and commenced full-scale operations in August 2023.」
The Kobe Science Park Center commenced full-scale operations in August 2023 following completion, bringing the facility expansion for increased drug-substance manufacturing capacity into the operational phase. - FY2023AdvancedAnnual report
「Capital expenditures for the consolidated fiscal year totaled ¥8,023 million, consisting mainly of ¥3,789 million for pharmaceutical manufacturing equipment and ¥1,647 million for research equipment. The Kobe Science Park Center was completed in November 2022 and is scheduled to commence full-scale operations in August 2023. Kobe Science Park Formulation Plant (provisional name): ¥20,000 million; December 2024; May 2026.」
Following completion, the Kobe Science Park Center progressed to the preparation stage for full-scale operations. In addition, the Company plans to continue expanding production capacity through the Kobe Science Park Formulation Plant, with total investment of ¥20 billion and completion scheduled for May 2026. - FY2023-Q3AchievedAnnual report
「The facility was completed in November 2022 and is scheduled to begin operations in the first quarter of the fiscal year ending March 2024.」
The pharmaceutical manufacturing equipment at the Kobe Science Park Center was confirmed to have been completed in November 2022. Operations are scheduled to begin in the first quarter of the fiscal year ending March 2024, marking a transition from completion of construction to preparations for operation. - FY2023-Q2AdvancedAnnual report
「Payment was completed on 11 October 2022. Following this acquisition, Mycenax Biotech Inc. became an equity-method affiliate of the Company. Number of shares acquired: 42 million; acquisition price: ¥6,271 million; number of shares held after the change: 42 million (voting rights ownership ratio: 20.46%).」
Payment for the subscription to the third-party allotment of shares by Mycenax Biotech Inc., a Taiwanese CDMO, was completed, making the company an equity-method affiliate. The transaction is intended to increase the flexibility of our in-house production capacity and accelerate production activities. - FY2023-Q2AdvancedAnnual report
「At a meeting of the Board of Directors held on 26 October 2022, we resolved to construct a new formulation plant (the New Plant) on land acquired on 24 March 2022 in Kobe Science Park, Kobe City.」
We resolved to construct a new formulation plant in Kobe Science Park, Kobe City. Total construction costs are approximately ¥20 billion, with construction scheduled to begin in November 2023 and completion scheduled for April 2025. The plant will expand contract manufacturing capacity for vaccines and manufacturing capacity for J-Brain Cargo®-related products. - FY2023-Q1AdvancedAnnual report
「At a meeting of the Board of Directors held on 27 July 2022, we resolved to subscribe to the third-party allotment of shares conducted by Mycenax Biotech Inc., a Taiwanese contract development and manufacturing organization for pharmaceuticals. Following this subscription, Mycenax Biotech Inc. will become an equity-method affiliate of the Company. To enable multiple research and development programs to progress in parallel, we will strengthen our relationship with Mycenax Biotech Inc., an established biopharmaceutical CDMO providing full-service operations, through this subscription, with the aim of increasing the flexibility of our in-house production capacity and accelerating production activities.」
As a means of expanding production capacity, we resolved to subscribe to a third-party allotment of shares by Mycenax Biotech Inc., a Taiwanese CDMO. The number of shares to be acquired is 42 million, the acquisition price is ¥6.2 billion, and the voting rights ownership ratio after the capital increase is expected to be 20.48%, making us the company's largest shareholder. The acquisition is scheduled to take place within 15 days of approval by the Taiwanese authorities and will be funded with internal resources. - FY2022AdvancedAnnual report
「In addition to the 6 products currently manufactured and marketed, we plan to manufacture and market more than 10 lysosomal disease therapies globally. Our current 4 domestic manufacturing sites are expected to lack sufficient capacity to ensure a stable supply.」
As the 4 domestic manufacturing sites are expected to lack sufficient capacity to supply more than 10 lysosomal disease therapies in the future, we are developing the Kobe Science Park Manufacturing Site. Total planned investment is ¥11.6 billion, with completion scheduled for October 2022. The vaccine drug-substance manufacturing site is scheduled to begin commercial production in the second half of 2023. - FY2021AdvancedAnnual report
「The following newly confirmed plans for major capital expenditures were in place at the end of the consolidated fiscal year.」
The plan to expand pharmaceutical manufacturing capacity at the Kobe Science Park Manufacturing Site (provisional name) has been finalized, with total planned investment of ¥11.6 billion, work scheduled to begin in July 2021 and completion scheduled for October 2022. - FY2020AdvancedAnnual report
「Total capital expenditures for the consolidated fiscal year were ¥5,296 million. The main components were ¥423 million for pharmaceutical manufacturing equipment and ¥4,403 million for research equipment.」
Capital expenditures for the year totaled ¥5,296 million, including ¥4,403 million for research equipment. The expansion of research-related facilities is also reflected in the increase in property, plant and equipment. - FY2020-Q3AdvancedAnnual report
「Property, plant and equipment increased by ¥3,299 million from the end of the previous consolidated fiscal year to ¥18,446 million, mainly due to the expansion of research-related facilities.」
Property, plant and equipment increased by ¥3,299 million from the end of the previous consolidated fiscal year due to the expansion of research-related facilities, reflecting the results of facility development in the financial position. - FY2019AdvancedAnnual report
「In April this year, we began construction of a second clinical-trial drug manufacturing center and are also preparing to build a new plant in the Grand Duchy of Luxembourg.」
In addition to utilizing existing sites, the company advanced to a new site-development stage with the start of construction of a second clinical-trial drug manufacturing center. - FY2017-Q3Cited as achievedAnnual report
「In the cell medicine field, we are also developing new regenerative medicine products at the Cell Processing Center completed in April last year.」
The Cell Processing Center completed in April last year is being used as a development site for current regenerative medicine products. - FY2017-Q1AchievedAnnual report
「In April this year, a new investigational drug manufacturing center and cell processing center were completed, accelerating the development of the groundbreaking Hunter syndrome enzyme replacement therapy JR-141, which uses the blood-brain barrier-penetrating technology J-Brain Cargo®, as well as new regenerative medicine products.」
The new clinical-trial drug manufacturing center and cell processing center were completed in April 2016, indicating that development of the sites had been completed. - FY2016First statedAnnual report
「April 2016: Opened a clinical-trial drug manufacturing center and a cell processing center in Nishi Ward, Kobe (Kobe High-Tech Park).」
The company's corporate history states that it opened a clinical-trial drug manufacturing center and a cell processing center in April 2016.